The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats
The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats
复制标题
吗替麦考酚酯对大鼠肺动脉高压的影响及机制
DOI：
10.1007/s00296-009-0966-8
复制
发表时间：
2010-01-01
影响因子：
4
通讯作者：
Jin, Mulan
中科院分区：
文献类型：
--
作者：
Zheng, Yi;Li, Mingwei;Jin, Mulan
肺动脉高压（PAH）是一种严重的临床和病理生理综合征，目前尚无有效的治疗方法。霉酚酸酯（Mycophenolatemofetil，MMF）是霉酚酸（Mycophenolicacid，MPA）的前体药物，具有免疫抑制作用，广泛应用于结缔组织疾病的治疗。其抗扩散作用是近年来发现的。因此，本研究拟通过观察霉酚酸酯对野百合碱诱导的肺动脉高压大鼠的作用，探讨霉酚酸酯治疗肺动脉高压的作用机制。结果证实，霉酚酸酯治疗可减轻肺动脉壁增厚，抑制异常血管重构，且本研究显示有效的MPA浓度在临床适用范围内，提示霉酚酸酯治疗人类PAH的巨大潜力。
Pulmonary arterial hypertension (PAH) is a severe clinical and pathophysiologic syndrome with no effective treatment at present. Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), has been applied widely to the treatment of connective tissue diseases with the effect of immunosuppressant. Its anti-proliferation has been found recently. Thereby, we tried to examine the effects of MMF on rats with PAH which was induced by monocrotaline injection, so as to investigate the mechanisms of treatment on PAH by MMF. The results substantiated that MMF therapy can alleviate thickening of pulmonary arterial walls and inhibit abnormal vascular remodeling, and the MPA concentrations which demonstrated efficacy in this study are within clinical applicable range, suggesting huge potentiality of MMF in the treatment of human PAH.